Abstract: A compound having formula I is useful for treating a neurodegenerative disease: or a pharmaceutically acceptable salt or ester thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8 are each independently hydroxyl, C1-4 alkyl, C1-4 alkoxyl, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C4-8, are specified substituents.

Abstract: A compound having formula IA is useful for treating a neurodegenerative disease: or a pharmaceutically acceptable salt or ester thereof, where R0, R1, R2, R7, R8 are delineated substituents; A1 is a C6-12 aryl group, C5-12 heteroaryl group, substituted 3-hydroxypyridin-4(1H)-one, with i hydrogen atoms replaced with R7 and j hydrogen atoms replaced with R8; p is an integer from 1 to 6; X1, Y1 are each independently CH or N; M is absent or a divalent linking moiety in which Z is repeated m times; m is an integer from 0 to 5; i, j are each independently 0, 1, 2, or 3; and o is 0, 1, 2, 3, or 4.

Abstract: A compound having formula I is useful for treating a neurodegenerative disease: or a pharmaceutically acceptable salt or ester thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8 are each independently hydroxyl, C1-4 alkyl, C1-4 alkoxyl, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C4-8, are specified substituents.

Abstract: A compound having formula IA is useful for treating a neurodegenerative disease: or a pharmaceutically acceptable salt or ester thereof, where R0, R1, R2, R7, R8 are delineated substituents; A1 is a C6-12 aryl group, C5-12 heteroaryl group, substituted 3-hydroxypyridin-4(1H)-one, with i hydrogen atoms replaced with R7 and j hydrogen atoms replaced with R8; p is an integer from 1 to 6; X1, Y1 are each independently CH or N; M is absent or a divalent linking moiety in which Z is repeated m times; m is an integer from 0 to 5; i, j are each independently 0, 1, 2, or 3; and o is 0, 1, 2, 3, or 4.

Abstract: A compound having formula IA is useful for treating a neurodegenerative disease: or a pharmaceutically acceptable salt or ester thereof, where R0, R1, R2, R7, R8 are delineated substituents; A1 is a C6-12 aryl group, C5-12 heteroaryl group, substituted 3-hydroxypyridin-4(1H)-one, with i hydrogen atoms replaced with R7 and j hydrogen atoms replaced with R8; p is an integer from 1 to 6; X1, Y1 are each independently CH or N; M is absent or a divalent linking moiety in which Z is repeated m times; m is an integer from 0 to 5; i, j are each independently 0, 1, 2, or 3; and o is 0, 1, 2, 3, or 4.

Abstract: A compound having formula I is useful for treating a neurodegenerative disease: R1 is an C1-12 organyl group; is a C1-12 heterocyclic ring system containing 5 to 12 ring atoms and up to three heteroatoms individually selected from the group consisting of N, O, S, and Se; R2 are C1-12 organyl groups; R7, R8 are each independently, hydrogen (H), hydroxyl, oxo (i.e., carbonyl), C1-8 alkyl, C1-8 alkoxyl, C2-8 alkenyl, C2-10 alkynyl, C5-7 cycloalkyl, C5-7 cycloalkenyl, halo, C1-4 aldehyde, or —NR4q where R4 is H, C1-8 alkyl, C2-8 alkenyl, C4-8 cycloalkyl, C4-8 cycloalkenyl, or C6-10 aryl; o is 0, 1, 2, 3, or 4; A is a C6-12 aryl group, C5-12 heteroaryl group, or an optionally substituted 3-hydroxypyridin-4(1H)-one; p is an integer from 1 to 6; and Zm is absent or a divalent linking moiety; and m is an integer representing the number of time Z is repeated.

Abstract: Certain 3,6-disubstituted and 2, 4, 5-trisubstituted pyran derivatives that exhibit potent activity on monoamine transport systems are provided. The 3, 6 and 2, 4, 5 pyrans are useful in probing the effects of their binding to monoamine transporter systems and the corresponding relationships to various afflictions affecting the CNS, or as a treatment for various CNS-related disorders in which the monoamine transport and related systems are implicated.

Abstract: Certain 3,6-disubstituted and 2,4,5-trisubstituted pyran derivatives that exhibit potent activity on monoamine transport systems are provided. The 3,6 and 2,4,5 pyrans are useful in probing the effects of their binding to monoamine transporter systems and the corresponding relationships to various afflictions affecting the CNS, or as a treatment for various CNS-related disorders in which the monoamine transport and related systems are implicated.

Abstract: A compound having formula I is useful for treating a neurodegenerative disease: R1 is an C1-12 organyl group; is a C1-12 heterocyclic ring system containing 5 to 12 ring atoms and up to three heteroatoms individually selected from the group consisting of N, O, S, and Se; R2 are C1-12 organyl groups; R7, R8 are each independently, hydrogen (H), hydroxyl, oxo (i.e., carbonyl), C1-8 alkyl, C1-8 alkoxyl, C2-8 alkenyl, C2-10 alkynyl, C5-7 cycloalkyl, C5-7 cycloalkenyl, halo, C1-4 aldehyde, or —NR4q where R4 is H, C1-8 alkyl, C2-8 alkenyl, C4-8 cycloalkyl, C4-8 cycloalkenyl, or C6-10 aryl; o is 0, 1, 2, 3, or 4; A is a C6-12 aryl group, C5-12 heteroaryl group, or an optionally substituted 3-hydroxypyridin-4(1H)-one; p is an integer from 1 to 6; and Zm is absent or a divalent linking moiety; and m is an integer representing the number of time Z is repeated.

Abstract: A precursor for the deposition of a thin film by atomic layer deposition is provided. The compound has the formula MxLy where M is a metal and L is an amidrazone-derived ligand or an amidate-derived ligand. A process of forming a thin film using the precursors is also provided.

Abstract: Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of antidepressants.

Abstract: Certain 3,6-disubstituted and 2, 4, 5-trisubstituted pyran derivatives that exhibit potent activity on monoamine transport systems are provided. The 3, 6 and 2, 4, 5 pyrans are useful in probing the effects of their binding to monoamine transporter systems and the corresponding relationships to various afflictions affecting the CNS, or as a treatment for various CNS-related disorders in which the monoamine transport and related systems are implicated.

Abstract: Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.

Abstract: Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.

Abstract: 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.

Abstract: Hybrid compounds containing an aminotetralin moiety or a heterocyclic and/or open chain analog thereof linked through an alkylene group to an aryl ring system-substituted piperidiene moiety exhibit high levels of CNS activity, in some cases exhibiting especially high relative binding efficiencies between D3 and D2 dopaminergic receptor subtypes.

Abstract: N- and O-substituted 4[2-diaromaticmethoxy and methylamino)alkyl] piperidines exhibit high CNS activity with respect to the dopamine transporter (DAT) and serotonin transporter (SERT). Preferred compounds exhibit highly differential behavior as between the DAT and SERT and between the DAT and the norepinephrine transporter (NET). The compounds have utility in treating CNS disorders, including but not limited to cocaine addiction, depression, and Parkinson's disease.

Abstract: A precursor for the deposition of a thin film by atomic layer deposition is provided. The compound has the formula MxLy where M is a metal and L is an amidrazone-derived ligand or an amidate-derived ligand. A process of forming a thin film using the precursors is also provided.

Abstract: Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.

Abstract: Novel 3,6-disubstituted pyrans, optionally with a further substituent at the 4-position, are monoamine reuptake inhibitors with activity profiles of anti-depressants.